1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;Circulation,2019
2. 2022 ACC Expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee;Writing;J Am Coll Cardiol,2022
3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020
4. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline;Alanaeme;Am Heart J Plus,2022
5. Recurrent atherosclerotic cardiovascular disease events potentially prevented with guideline-recommended cholesterol-lowering therapy following myocardial infarction;Sakhuja;Cardiovasc Drugs Ther,2023